Biotech Merger Creates OSPRI to Revolutionize Infectious Disease Testing with $30M Backing
The merger of Community Direct DX, Scienetix, and Advanta Genetics R&D into OSPRI creates a vertically-integrated molecular testing platform that reduces PCR testing costs by 20-50% and time by 50-70%, addressing critical accessibility barriers in healthcare diagnostics.
The merger of Community Direct DX, Scienetix, and Advanta Genetics R&D has formed OSPRI, establishing one of the world's first fully vertically-integrated molecular testing platforms specializing in PCR-based infectious disease detection. This consolidation addresses fundamental challenges in healthcare diagnostics by reducing both cost and complexity barriers that have historically limited PCR testing adoption.
OSPRI's comprehensive approach covers the entire testing ecosystem, from assay development and manufacturing to lab buildout, revenue cycle management, and regulatory support. This end-to-end solution enables healthcare providers to operate high-complexity laboratories in-house with improved speed, accuracy, and financial control across multiple clinical segments including women's health, primary care, urgent care, urology, hospitals, and clinical reference laboratories.
The strategic merger is supported by up to $30 million in funding from Catalio Capital Management, a healthcare investment firm with deep diagnostics expertise. This financial backing will accelerate OSPRI's platform development and national expansion initiatives, positioning the company to meet growing demand for accessible, provider-centric diagnostics.
Technological advancements form the core of OSPRI's value proposition, delivering a 20-50% reduction in overall testing costs and a 50-70% decrease in testing time and workflow steps. The platform increases testing capacity by up to four times while reducing lab errors through simplified workflows. With a comprehensive menu of 80+ PCR tests covering 250+ pathogens and antimicrobial resistance genes, OSPRI offers customized assays tailored to specific provider specialties and patient populations.
The company's scientific leadership, including Chief Science Officer Dr. Rahul Sharma, Chief Innovation Officer Dr. Sadia Almas, and Chief Clinical Officer Dr. Alaina Vincent, brings together complementary expertise from the founding entities. Community Direct DX contributes nationwide laboratory deployment experience having launched over 60 labs since 2015, Scienetix adds molecular bioengineering capabilities, and Advanta R&D brings high-resolution genomics advancements and public health initiative experience.
Current production capabilities demonstrate significant scale, with OSPRI delivering over 40,000 tests daily with multilayered quality control systems. Headquartered in McKinney, Texas, the company serves clients across 20 states and multiple clinical specialties, with plans to expand its R&D team by 40% and grow commercial operations by 25% over the next 12-24 months. This growth trajectory reflects the increasing demand for cost-effective, rapid infectious disease testing solutions that maintain clinical excellence while improving accessibility for diverse patient populations.